Exclusive Summary

• High-Scarcity Validated Target: GPC3/CD3 bispecific antibody targeting Hypatocellular Carcinoma (HCC), a therapeutic area with limited global exploration and high unmet needs.
• Superior Efficacy Data: Demonstrated significant anti-tumor activity in in-vivo xenograft models, achieving Complete Response (CR) at medium to high doses with high specificity.
• Distinct Competitive Advantages: Highlights 'good safety profile' and 'low-cost advantage' compared to global competitors (e.g., Chugai, Xencor), offering pricing flexibility.
• Global Strategic Positioning: Currently in the clinical phase with a layout suggesting dual US/China regulatory capabilities, positioning it as a leading asset in its region.

Asset Materials

Contact Us for Full Materials